• Receipts from customers of $2.7M with positive net cashflow from operations of $0.2M
• Positive net cash inflow from operations of ~$1.3M for the full year
• Second TrialsWest site opened in 2024 in Osborne Park, WA, achieved profitability

Resonance Health Ltd (ASX: RHT) released its Appendix 4C and Quarterly Activities & Cashflow Report for the quarter ended 30th June 2025. The company made significant progress in each of its 3-business focus areas; (i) Clinical Trial Management CRO Services (Resonance Clinical), (ii) Software-as-a-Medical Device Image Analysis Services (SaMD), and (iii) Clinical Trial Site Services (TrialsWest). Resonance Clinical progressed its major global-pharma clinical trial contracts, with the first trial successfully completed and the second $13.8M trial on track. The TrialsWest business continued to expand, with the second site in Osborne Park, WA, achieving profitability during the quarter, and a third site secured in Mandurah, WA. The SaMD division secured ~$4.5M in new or extended service contracts with four global pharma companies. The company also commenced commercial testing of a new 'bridge' technology to improve customer experience by integrating its systems with customers' PACS platforms. The company reported positive net operating cash inflow of $0.2M for the quarter and $1.3M for the full year, with total customer receipts of $2.7M for the quarter.

The company enters FY26 with major clinical trial contracts underway or in the bid process, growing demand for SaMD services, and an expanding TrialsWest footprint, positioning it for sustained revenue growth and operational leverage.

The continued execution of the company's strategy across its three business segments - Resonance Clinical, SaMD, and TrialsWest - positions it for sustained revenue growth and operational leverage.